Karen L Reckamp

Title(s)HS Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol. Oncologist. 2024 Apr 10. Neal JW, Minichiello K, Brennick R, Huang RSP, Hiemenz MC, Amler C, Patel J, Herbst R, Reckamp KL, Borghaei H, Highleyman L, Redman MW, Pasquina LW, Kozono DE. PMID: 38597608.
      View in: PubMed   Mentions:
    2. Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer. Anticancer Drugs. 2024 Mar 22. Ferreira M, Ebia MI, Reckamp KL. PMID: 38527329.
      View in: PubMed   Mentions:    Fields:    
    3. Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175. Oncologist. 2024 Jan 05; 29(1):47-56. Gentzler RD, Mohindra NA, Jalal SI, Reckamp KL, Hall RD, Hanna NH, Chae YK, Koczywas M, Helenowski IB, Patel JD. PMID: 37390616; PMCID: PMC10769801.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    4. Moving Toward Rationale Phase 3 Designs for Advanced NSCLC. J Thorac Oncol. 2023 12; 18(12):1629-1631. Ferreira M, Redman MW, Reckamp KL. PMID: 37993216.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT). Lung Cancer. 2023 12; 186:107423. Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U. PMID: 37995456.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Low booster uptake in cancer patients despite health benefits. medRxiv. 2023 Oct 26. Figueiredo JC, Levy J, Choi SY, Xu AM, Merin NM, Hamid O, Lemos T, Nguyen N, Nadri M, Gonzalez A, Mahov S, Darrah JM, Gong J, Paquette RL, Mita AC, Vescio RA, Salvy SJ, Mehmi I, Hendifar AE, Natale R, Tourtellotte WG, Krishnan Ramanujan V, Huynh CA, Sobhani K, Reckamp KL, Merchant AA. PMID: 37961284; PMCID: PMC10635201.
      View in: PubMed   Mentions:
    7. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan; 35(1):77-90. Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC, MARIPOSA-2 Investigators. PMID: 37879444.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    8. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J Clin Oncol. 2023 Dec 10; 41(35):5363-5375. Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Jänne PA. PMID: 37689979; PMCID: PMC10713116.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    9. Investigation of liquid biopsy analytes in peripheral blood of individuals after SARS-CoV-2 infection. EBioMedicine. 2023 Apr; 90:104519. Qi E, Courcoubetis G, Liljegren E, Herrera E, Nguyen N, Nadri M, Ghandehari S, Kazemian E, Reckamp KL, Merin NM, Merchant A, Mason J, Figueiredo JC, Shishido SN, Kuhn P. PMID: 36921564; PMCID: PMC10008671.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    10. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023 04; 178:166-171. Park K, Sabari JK, Haura EB, Shu CA, Spira A, Salgia R, Reckamp KL, Sanborn RE, Govindan R, Bauml JM, Curtin JC, Xie J, Roshak A, Lorenzini P, Millington D, Thayu M, Knoblauch RE, Cho BC. PMID: 36868177.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    11. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. Target Oncol. 2023 01; 18(1):105-118. Kollmannsberger C, Hurwitz H, Bazhenova L, Cho BC, Hong D, Park K, Reckamp KL, Sharma S, Der-Torossian H, Christensen JG, Faltaos D, Potvin D, Tassell V, Chao R, Shapiro GI. PMID: 36459255.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    12. Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma. J Natl Compr Canc Netw. 2022 11 17; 21(1):6-11. Chen L, Davelaar J, Gaddam S, Kosari K, Nissen N, Chaux G, Lee C, Vail E, Hendifar A, Gong J, Reckamp K, Osipov A. PMID: 36395704.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Editorial: Impact of immunotherapy in lung cancer. Front Oncol. 2022; 12:1083524. Ferreira M, Reckamp KL. PMID: 36439462; PMCID: PMC9693746.
      View in: PubMed   Mentions: 1  
    14. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 03; 165(3):828-839.e5. Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM. PMID: 36369159; PMCID: PMC10288861.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    15. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. JTO Clin Res Rep. 2022 Sep; 3(9):100385. Gettinger SN, Huber RM, Kim DW, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz-Ares Rodríguez LG, West HL, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim SW, Ahn MJ, Kim ES, Groen HJM, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR. PMID: 36065449; PMCID: PMC9440305.
      View in: PubMed   Mentions: 6  
    16. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. Curr Med Res Opin. 2022 Sep; 38(9):1587-1593. Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Kay S, Walton LJ, Shen J, Popat S, Camidge DR. PMID: 35815801.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO Clin Res Rep. 2022 Sep; 3(9):100381. Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, Ma PC, Nagasaka M, Reckamp KL, Abraham J, Uprety D, Wang F, Xiu J, Zhang J, Cheng H, Halmos B. PMID: 36082279; PMCID: PMC9445394.
      View in: PubMed   Mentions: 5  
    18. Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data. Drugs Real World Outcomes. 2022 Sep; 9(3):333-345. Nieva J, Reckamp KL, Potter D, Taylor A, Sun P. PMID: 35661118; PMCID: PMC9392819.
      View in: PubMed   Mentions: 3  
    19. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol. 2022 07 20; 40(21):2295-2306. Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. PMID: 35658002; PMCID: PMC9287284.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    20. Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. Future Oncol. 2022 Jun; 18(20):2499-2510. Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Walton LJ, Kay S, Cichewicz A, Neupane B, Fahrbach K, Popat S, Camidge DR. PMID: 35608148.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infect Dis. 2022 Jun; 9(6):ofac171. Figueiredo JC, Hirsch FR, Kushi LH, Nembhard WN, Crawford JM, Mantis N, Finster L, Merin NM, Merchant A, Reckamp KL, Melmed GY, Braun J, McGovern D, Parekh S, Corley DA, Zohoori N, Amick BC, Du R, Gregersen PK, Diamond B, Taioli E, Sariol C, Espino A, Weiskopf D, Gifoni A, Brien J, Hanege W, Lipsitch M, Zidar DA, Scheck McAlearney A, Wajnberg A, LaBaer J, Yvonne Lewis E, Binder RA, Moormann AM, Forconi C, Forrester S, Batista J, Schieffelin J, Kim D, Biancon G, VanOudenhove J, Halene S, Fan R, Barouch DH, Alter G, Pinninti S, Boppana SB, Pati SK, Latting M, Karaba AH, Roback J, Sekaly R, Neish A, Brincks AM, Granger DA, Karger AB, Thyagarajan B, Thomas SN, Klein SL, Cox AL, Lucas T, Furr-Holden D, Key K, Jones N, Wrammerr J, Suthar M, Yu Wong S, Bowman NM, Simon V, Richardson LD, McBride R, Krammer F, Rana M, Kennedy J, Boehme K, Forrest C, Granger SW, Heaney CD, Knight Lapinski M, Wallet S, Baric RS, Schifanella L, Lopez M, Fernández S, Kenah E, Panchal AR, Britt WJ, Sanz I, Dhodapkar M, Ahmed R, Bartelt LA, Markmann AJ, Lin JT, Hagan RS, Wolfgang MC, Skarbinski J. PMID: 35765315; PMCID: PMC9129196.
      View in: PubMed   Mentions: 4  
    22. Cancer Screening Practices Among Healthcare Workers During the COVID-19 Pandemic. Front Public Health. 2022; 10:801805. Datta GD, Lauzon M, Salvy SJ, Hussain SK, Ghandehari S, Merchant A, Merin NM, Reckamp K, Figueiredo JC. PMID: 35372243; PMCID: PMC8967182.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    23. Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC. Clin Transl Sci. 2022 05; 15(5):1143-1154. Gupta N, Reckamp KL, Camidge DR, Kleijn HJ, Ouerdani A, Bellanti F, Maringwa J, Hanley MJ, Wang S, Zhang P, Venkatakrishnan K. PMID: 35041775; PMCID: PMC9099121.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    24. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. J Thorac Oncol. 2022 05; 17(5):661-674. Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Métivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V, TERAVOLT study group. PMID: 35121086; PMCID: PMC8804493.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    25. A Lung Cancer Screening Education Program Impacts both Referral Rates and Provider and Medical Assistant Knowledge at Two Federally Qualified Health Centers. Clin Lung Cancer. 2022 06; 23(4):356-363. Akhtar A, Sosa E, Castro S, Sur M, Lozano V, D'Souza G, Yeung S, Macalintal J, Patel M, Zou X, Wu PC, Silver E, Sandoval J, Gray SW, Reckamp KL, Kim JY, Sun V, Raz DJ, Erhunmwunsee L. PMID: 34991968; PMCID: PMC9149065.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2022 01; 89(1):105-115. Padda SK, Reckamp KL, Koczywas M, Neal JW, Kawashima J, Kong S, Huang DB, Kowalski M, Wakelee HA. PMID: 34773474; PMCID: PMC8739290.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    27. Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. Cancer Res. 2021 12 15; 81(24):6273-6280. Figueiredo JC, Merin NM, Hamid O, Choi SY, Lemos T, Cozen W, Nguyen N, Finster LJ, Foley J, Darrah J, Gong J, Paquette R, Mita AC, Vescio R, Mehmi I, Basho R, Tourtellotte WG, Huynh CA, Melmed GY, Braun J, McGovern DPB, Mengesha E, Botwin G, Prostko JC, Frias EC, Stewart JL, Joung S, Van Eyk J, Ebinger JE, Cheng S, Sobhani K, Reckamp KL, Merchant A. PMID: 34759001; PMCID: PMC9060668.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsPHPublic Health
    28. Symptomology following mRNA vaccination against SARS-CoV-2. Prev Med. 2021 12; 153:106860. Ebinger JE, Lan R, Sun N, Wu M, Joung S, Botwin GJ, Botting P, Al-Amili D, Aronow H, Beekley J, Coleman B, Contreras S, Cozen W, Davis J, Debbas P, Diaz J, Driver M, Fert-Bober J, Gu Q, Heath M, Herrera E, Hoang A, Hussain SK, Huynh C, Kim L, Kittleson M, Liu Y, Lloyd J, Luong E, Malladi B, Merchant A, Merin N, Mujukian A, Nguyen N, Nguyen TT, Pozdnyakova V, Rashid M, Raedschelders K, Reckamp KL, Rhoades K, Sternbach S, Vallejo R, White S, Tompkins R, Wong M, Arditi M, Figueiredo JC, Van Eyk JE, Miles PB, Chavira C, Shane R, Sobhani K, Melmed GY, McGovern DPB, Braun JG, Cheng S, Minissian MB. PMID: 34687733; PMCID: PMC8527734.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsPHPublic Health
    29. SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment. Ann Oncol. 2022 01; 33(1):109-111. Figueiredo JC, Ihenacho U, Merin NM, Hamid O, Darrah J, Gong J, Paquette R, Mita AC, Vescio R, Mehmi I, Basho R, Salvy SJ, Shirazipour CH, Caceres N, Finster LJ, Coleman B, Arnow HU, Florindez L, Sobhani K, Prostko JC, Frias EC, Stewart JL, Merchant A, Reckamp KL. PMID: 34687893; PMCID: PMC8527840.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsPHPublic Health
    30. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 01; 23(1):72-81. Page RD, Drusbosky LM, Dada H, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA, Leighl NB. PMID: 34782240.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    31. First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors. Oncologist. 2021 11; 26(11):925-e1918. Do KT, Chow LQM, Reckamp K, Sanborn RE, Burris H, Robert F, Camidge DR, Steuer CE, Strickler JH, Weise A, Specht JM, Gutierrez M, Haughney P, Hengel S, Derleth CL, Yap TA. PMID: 34288257; PMCID: PMC8571760.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    32. Recall of Genomic Testing Results Among Patients with Cancer. Oncologist. 2021 12; 26(12):e2302-e2305. Wing SE, Hu H, Lopez L, Solomon I, Shen J, Raquel C, Sur M, Chao J, Cristea M, Fakih M, Mortimer J, Pal S, Reckamp K, Yuan Y, Gray SW. PMID: 34355454; PMCID: PMC8649013.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    33. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 10 20; 39(30):3391-3402. Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC. PMID: 34339292; PMCID: PMC8791812.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCTClinical Trials
    34. Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer. Protein Cell. 2022 02; 13(2):82-89. Liu B, Duenas D, Zheng L, Reckamp K, Shen B. PMID: 34319535; PMCID: PMC8783936.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. Pharmaceutics. 2021 Jun 21; 13(6). Ferreira M, Secher T, Heuze-Vourc'H N, Reckamp KL. PMID: 34205484; PMCID: PMC8234109.
      View in: PubMed   Mentions: 2  
    36. The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2021 08; 30(8):1498-1505. Erhunmwunsee L, Wing SE, Shen J, Hu H, Sosa E, Lopez LN, Raquel C, Sur M, Ibarra-Noriega P, Currey M, Lee J, Kim JY, Raz DJ, Amini A, Sampath S, Koczywas M, Massarelli E, West HL, Reckamp KL, Kittles RA, Salgia R, Seewaldt VL, Neuhausen SL, Gray SW. PMID: 34088750; PMCID: PMC8338883.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    37. Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers (Basel). 2021 Jun 03; 13(11). Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Chao J, Chen C, Nasser MW, Chirravuri-Venkata R, Jain M, Smith L, Yost SE, Reckamp KL, Pillai R, Arvanitis L, Afkhami M, Wang EW, Chung V, Cristea M, Fakih M, Koczywas M, Massarelli E, Mortimer J, Yuan Y, Batra SK, Pal S, Salgia R. PMID: 34204917; PMCID: PMC8199748.
      View in: PubMed   Mentions: 8  
    38. Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers (Basel). 2021 May 28; 13(11). Zhao D, Li H, Mambetsariev I, Chen C, Pharaon R, Fricke J, Baroz AR, Kulkarni P, Xing Y, Massarelli E, Koczywas M, Reckamp KL, Margolin K, Salgia R. PMID: 34071259; PMCID: PMC8198372.
      View in: PubMed   Mentions: 1  
    39. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clin Lung Cancer. 2021 11; 22(6):541-548. Riess JW, Reckamp KL, Frankel P, Longmate J, Kelly KA, Gandara DR, Weipert CM, Raymond VM, Keer HN, Mack PC, Newman EM, Lara PN. PMID: 34140248; PMCID: PMC9239707.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    40. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107. Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Husain H, Reckamp KL, Koczywas M, Massarelli E, Bild AH, Salgia R. PMID: 33878340; PMCID: PMC8449001.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    41. Germline mutations and age at onset of lung adenocarcinoma. Cancer. 2021 08 01; 127(15):2801-2806. Reckamp KL, Behrendt CE, Slavin TP, Gray SW, Castillo DK, Koczywas M, Cristea MC, Babski KM, Stearns D, Marcum CA, Rodriguez YP, Hass AJ, Vecchio MM, Mora P, Cervantes AE, Sand SR, Mejia RM, Tsou TC, Salgia R, Weitzel JN. PMID: 33858029; PMCID: PMC8794435.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    42. Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach. J Thorac Oncol. 2021 02; 16(2):178-182. Padda SK, Reckamp KL. PMID: 33494922.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    43. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. Future Sci OA. 2020 Nov 25; 7(2):FSO662. Reckamp KL, McQuerry JA, Mambetsariev I, Pharaon R, Yost SE, Fricke J, Mirzapoiazova T, Pillai RK, Khan Z, Fakih M, Yuan Y, Koczywas M, Massarelli E, Kulkarni P, Pal SK, Sattler M, Bild A, Salgia R. PMID: 33437521; PMCID: PMC7787173.
      View in: PubMed   Mentions: 1  
    44. Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clin Res Rep. 2021 Feb; 2(2):100114. Yang JC, Reckamp KL, Kim YC, Novello S, Smit EF, Lee JS, Su WC, Akerley WL, Blakely CM, Groen HJM, Bazhenova L, Carcereny Costa E, Chiari R, Hsia TC, Golsorkhi T, Despain D, Shih D, Popat S, Wakelee H. PMID: 34589984; PMCID: PMC8474221.
      View in: PubMed   Mentions: 8  
    45. Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. J Thorac Dis. 2020 Sep; 12(9):5086-5095. Amanam I, Mambetsariev I, Gupta R, Achuthan S, Wang Y, Pharaon R, Massarelli E, Koczywas M, Reckamp K, Salgia R. PMID: 33145085; PMCID: PMC7578487.
      View in: PubMed   Mentions: 21  
    46. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 08 27; 383(9):813-824. Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. PMID: 32846060; PMCID: PMC7506467.
      View in: PubMed   Mentions: 252     Fields:    Translation:HumansCTClinical Trials
    47. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer. 2020 10 01; 126(19):4353-4361. Durm GA, Jabbour SK, Althouse SK, Liu Z, Sadiq AA, Zon RT, Jalal SI, Kloecker GH, Williamson MJ, Reckamp KL, Langdon RM, Kio EA, Gentzler RD, Adesunloye BA, Harb WA, Walling RV, Titzer ML, Hanna NH. PMID: 32697352; PMCID: PMC10865991.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    48. Immunotherapy in Advanced Lung Cancer. Oncology (Williston Park). 2020 Jul 15; 34(7):272-279. Huang J, Reckamp KL. PMID: 32674216.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    49. Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncol Pract. 2021 02; 17(2):e257-e265. Salgia R, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Hozo I, Chen C, Koczywas M, Massarelli E, Reckamp K, Djulbegovic B. PMID: 32639928; PMCID: PMC8258019.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    50. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. Clin Lung Cancer. 2020 11; 21(6):545-552.e1. Reckamp KL, Patil T, Kirtane K, Rich TA, Espenschied CR, Weipert CM, Raymond VM, Santana-Davila R, Doebele RC, Baik CS. PMID: 32665165; PMCID: PMC9227978.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    51. Immunotherapy in Advanced Non-Small Cell Lung Cancer. Semin Respir Crit Care Med. 2020 Jun; 41(3):400-408. Huang J, Reckamp KL. PMID: 32450594.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    52. Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer. 2020 08; 146:174-181. Zhao D, Mambetsariev I, Li H, Chen C, Fricke J, Fann P, Kulkarni P, Xing Y, Lee PP, Bild A, Massarelli E, Koczywas M, Reckamp K, Salgia R. PMID: 32554069; PMCID: PMC8158847.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    53. Non-Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment. MDM Policy Pract. 2020 Jan-Jun; 5(1):2381468320922208. MacEwan JP, Gupte-Singh K, Zhao LM, Reckamp KL. PMID: 32548305; PMCID: PMC7249575.
      View in: PubMed   Mentions: 1  
    54. Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. JCO Precis Oncol. 2020; 4. Solomon IB, McGraw S, Shen J, Albayrak A, Alterovitz G, Davies M, Del Vecchio Fitz C, Freedman RA, Lopez LN, Sholl LM, Van Allen E, Mortimer J, Fakih M, Pal S, Reckamp KL, Yuan Y, Gray SW. PMID: 32923887; PMCID: PMC7446413.
      View in: PubMed   Mentions: 7     Fields:    
    55. Molecular Targets Beyond the Big 3. Thorac Surg Clin. 2020 May; 30(2):157-164. Reckamp KL. PMID: 32327174.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    56. Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. Oncologist. 2020 07; 25(7):562-e1012. Patel SP, Pakkala S, Pennell NA, Reckamp KL, Lanzalone S, Polli A, Tarazi J, Robert-Vizcarrondo F. PMID: 32048771; PMCID: PMC7356710.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    57. Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS One. 2020; 15(2):e0228188. Mambetsariev I, Wang Y, Chen C, Nadaf S, Pharaon R, Fricke J, Amanam I, Amini A, Bild A, Chu P, Erhunmwunsee L, Kim J, Munu J, Pillai R, Raz D, Sampath S, Vora L, Qiu F, Smith L, Batra SK, Massarelli E, Koczywas M, Reckamp K, Salgia R. PMID: 32045431; PMCID: PMC7012442.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    58. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019 12; 17(12):1464-1472. Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K, OCN, Hughes M. PMID: 31805526.
      View in: PubMed   Mentions: 360     Fields:    Translation:Humans
    59. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol. 2020 03; 15(3):404-415. Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MJ, Kim ES, Kerstein D, Groen HJM, Camidge DR. PMID: 31756496.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    60. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. Lung Cancer. 2019 12; 138:124-130. Hida T, Velcheti V, Reckamp KL, Nokihara H, Sachdev P, Kubota T, Nakada T, Dutcus CE, Ren M, Tamura T. PMID: 31710864.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    61. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. J Thorac Oncol. 2019 11; 14(11):1901-1911. Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM. PMID: 31446141; PMCID: PMC6823161.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    62. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clin Cancer Res. 2019 10 01; 25(19):5832-5842. Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gautschi O. PMID: 31300450; PMCID: PMC6774853.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    63. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer. 2019 07; 133:136-143. Shinde A, Horne ZD, Li R, Glaser S, Massarelli E, Koczywas M, Erhunmwunsee L, Reckamp KL, Weksler B, Salgia R, Beriwal S, Amini A. PMID: 31200820.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    64. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019 Aug 01; 25(15):4691-4700. Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA. PMID: 30988079.
      View in: PubMed   Mentions: 223     Fields:    Translation:Humans
    65. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol. 2019 04; 42(4):337-344. Gupta R, Amanam I, Rahmanuddin S, Mambetsariev I, Wang Y, Huang C, Reckamp K, Vora L, Salgia R. PMID: 30741758; PMCID: PMC7597761.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    66. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303). Front Oncol. 2019; 9:132. Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN. PMID: 30915273; PMCID: PMC6421302.
      View in: PubMed   Mentions: 22  
    67. Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. J Thorac Oncol. 2019 02; 14(2):e29-e30. Tsou TC, Gowen K, Ali SM, Miller VA, Schrock AB, Lovly CM, Reckamp KL. PMID: 30683295.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    68. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285. Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV. PMID: 30550363; PMCID: PMC7001776.
      View in: PubMed   Mentions: 172     Fields:    Translation:Humans
    69. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discov. 2019 03; 9(3):384-395. Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ. PMID: 30487236; PMCID: PMC6397691.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    70. EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2018 Nov; 2:1-13. Goldman JW, Karlovich C, Sequist LV, Melnikova V, Franovic A, Gadgeel SM, Reckamp KL, Camidge DR, Pérol M, Ou SI, Liu SV, Yu HA, Soria JC, Socinski MA, Mekhail TM, Solomon BJ, Natale RB, Otterson GA, Papadimitrakopoulou V, Langer CJ, Neal JW, Despain D, Yurasov S, Litten JB, Erlander M, Raponi M, Wakelee HA. PMID: 35135111.
      View in: PubMed   Mentions: 5     Fields:    
    71. Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. Cancer Biol Ther. 2018; 19(11):1023-1032. Wang J, Mirzapoiazova T, Carol Tan YH, Pang KM, Pozhitkov A, Wang Y, Wang Y, Mambetsariev B, Wang E, Nasser MW, Batra SK, Raz D, Reckamp K, Kulkarni P, Zheng Y, Salgia R. PMID: 30311833; PMCID: PMC6301806.
      View in: PubMed   Mentions: 5     Fields:    
    72. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer. Curr Med Res Opin. 2019 04; 35(4):569-576. Reckamp K, Lin HM, Huang J, Proskorovsky I, Reichmann W, Krotneva S, Kerstein D, Huang H, Lee J. PMID: 30286627.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    73. A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 10; 82(4):723-732. Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM. PMID: 30128950; PMCID: PMC6342617.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    74. The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. Clin Cancer Res. 2018 12 01; 24(23):6053-6065. Gu L, Lingeman R, Yakushijin F, Sun E, Cui Q, Chao J, Hu W, Li H, Hickey RJ, Stark JM, Yuan YC, Chen Y, Vonderfecht SL, Synold TW, Shi Y, Reckamp KL, Horne D, Malkas LH. PMID: 29967249; PMCID: PMC6279569.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    75. Real-World Pseudoprogression: an Uncommon Phenomenon. J Thorac Oncol. 2018 07; 13(7):880-882. Reckamp KL. PMID: 29935844.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    76. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 07; 16(7):807-821. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 30006423.
      View in: PubMed   Mentions: 243     Fields:    Translation:Humans
    77. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 09; 123:91-98. Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. PMID: 30089602; PMCID: PMC6118115.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    78. Preparing Cancer Patients and Family Caregivers for Lung Surgery: Development of a Multimedia Self-Management Intervention. J Cancer Educ. 2018 06; 33(3):557-563. Sun V, Kim JY, Raz DJ, Chang W, Erhunmwunsee L, Uranga C, Ireland AM, Reckamp K, Tiep B, Hayter J, Lew M, Ferrell B, McCorkle R. PMID: 27542378; PMCID: PMC5573658.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    79. Therapeutic antibodies: A new era in the treatment of respiratory diseases? Pharmacol Ther. 2018 09; 189:149-172. Sécher T, Guilleminault L, Reckamp K, Amanam I, Plantier L, Heuzé-Vourc'h N. PMID: 29730443.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    80. Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2018 05; 16(5S):601-604. Reckamp KL. PMID: 29784736.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    81. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res. 2018 06 15; 24(12):2771-2779. Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA. PMID: 29563138; PMCID: PMC6004248.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    82. Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. Oncologist. 2018 07; 23(7):776-781. Suh JH, Schrock AB, Johnson A, Lipson D, Gay LM, Ramkissoon S, Vergilio JA, Elvin JA, Shakir A, Ruehlman P, Reckamp KL, Ou SI, Ross JS, Stephens PJ, Miller VA, Ali SM. PMID: 29540602; PMCID: PMC6058345.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    83. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10; 35(35):3924-3933. Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. PMID: 29023213; PMCID: PMC6075826.
      View in: PubMed   Mentions: 420     Fields:    Translation:HumansCTClinical Trials
    84. Urine test for EGFR analysis in patients with non-small cell lung cancer. J Thorac Dis. 2017 Oct; 9(Suppl 13):S1323-S1331. Franovic A, Raymond VM, Erlander MG, Reckamp KL. PMID: 29184671; PMCID: PMC5676103.
      View in: PubMed   Mentions: 15  
    85. Triptolide-Assisted Phosphorylation of p53 Suppresses Inflammation-Induced NF-κB Survival Pathways in Cancer Cells. Mol Cell Biol. 2017 08 01; 37(15). Zheng L, Jia J, Dai H, Wan L, Liu J, Hu L, Zhou M, Qiu M, Chen X, Chang L, Kim JY, Reckamp K, Raz DJ, Xia Z, Shen B. PMID: 28533220; PMCID: PMC5514447.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    86. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017 Jul 01; 35(19):2184-2192. Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE, Alliance for Clinical Trials in Oncology. PMID: 28489511; PMCID: PMC5493050.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    87. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017 Aug 01; 35(22):2490-2498. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR. PMID: 28475456.
      View in: PubMed   Mentions: 251     Fields:    Translation:HumansCTClinical Trials
    88. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clin Cancer Res. 2017 Aug 15; 23(16):4556-4568. Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM. PMID: 28468947; PMCID: PMC5599263.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCellsCTClinical Trials
    89. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 04; 15(4):504-535. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 28404761.
      View in: PubMed   Mentions: 605     Fields:    Translation:Humans
    90. A Multimedia Self-management Intervention to Prepare Cancer Patients and Family Caregivers for Lung Surgery and Postoperative Recovery. Clin Lung Cancer. 2017 05; 18(3):e151-e159. Sun V, Raz DJ, Ruel N, Chang W, Erhunmwunsee L, Reckamp K, Tiep B, Ferrell B, McCorkle R, Kim JY. PMID: 28233696; PMCID: PMC5413411.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    91. Immunotherapy improves the prognosis of lung cancer: do we have to change intensive care unit admission and triage guidelines? Crit Care. 2017 Jan 27; 21(1):18. Guillon A, Reckamp KL, Heuzé-Vourc'h N. PMID: 28126007; PMCID: PMC5270208.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    92. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566. Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM, Blumenschein G. PMID: 27876675.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    93. The impact of lung cancer surgery on quality of life trajectories in patients and family caregivers. Lung Cancer. 2016 11; 101:35-39. Kim JY, Sun V, Raz DJ, Williams AC, Fujinami R, Reckamp K, Koczywas M, Cristea M, Hurria A, Ferrell B. PMID: 27794406; PMCID: PMC5123701.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    94. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. J Thorac Oncol. 2016 Oct; 11(10):1690-700. Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S, Geis J, Berz D, Mann E, Matheny S, Rolfe L, Raponi M, Erlander MG, Gadgeel S. PMID: 27468937.
      View in: PubMed   Mentions: 134     Fields:    Translation:Humans
    95. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016 07; 14(7):825-36. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 27407123; PMCID: PMC10187059.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    96. Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France. MAbs. 2016 Aug-Sep; 8(6):999-1009. Desoubeaux G, Reichert JM, Sleeman M, Reckamp KL, Ryffel B, Adamczewski JP, Sweeney TD, Vanbever R, Diot P, Owen CA, Page C, Lerondel S, Le Pape A, Heuze-Vourc'h N. PMID: 27266390; PMCID: PMC4968091.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    97. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 03; 14(3):255-64. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 26957612; PMCID: PMC10181272.
      View in: PubMed   Mentions: 205     Fields:    Translation:Humans
    98. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016 Apr; 27(4):693-9. Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee MJ, Lee S, Trepel JB, Reckamp KL, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G. PMID: 26802155; PMCID: PMC4803455.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    99. Advances in immunotherapy for non-small cell lung cancer. Clin Adv Hematol Oncol. 2015 Dec; 13(12):847-53. Reckamp KL. PMID: 27058851.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    100. Long-Term Effect of an Interdisciplinary Supportive Care Intervention for Lung Cancer Survivors After Surgical Procedures. Ann Thorac Surg. 2016 Feb; 101(2):495-502; discussion 502-3. Raz DJ, Sun V, Kim JY, Williams AC, Koczywas M, Cristea M, Reckamp K, Hayter J, Tiep B, Ferrell B. PMID: 26443881; PMCID: PMC4718894.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    101. Interdisciplinary Palliative Care for Patients With Lung Cancer. J Pain Symptom Manage. 2015 Dec; 50(6):758-67. Ferrell B, Sun V, Hurria A, Cristea M, Raz DJ, Kim JY, Reckamp K, Williams AC, Borneman T, Uman G, Koczywas M. PMID: 26296261; PMCID: PMC4666729.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    102. Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer. Br J Cancer. 2015 Jul 28; 113(3):484-91. Korbakis D, Dimitromanolakis A, Prassas I, Davis GJ, Barber E, Reckamp KL, Blasutig I, Diamandis EP. PMID: 26180921; PMCID: PMC4522621.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    103. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. PMID: 26106072; PMCID: PMC4592395.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    104. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. PMID: 26028407; PMCID: PMC4681400.
      View in: PubMed   Mentions: 3809     Fields:    Translation:HumansCTClinical Trials
    105. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer. 2015 Sep 15; 121(18):3298-306. Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin RA, Fishbein MC, Elashoff RM, Dubinett SM. PMID: 26033830; PMCID: PMC4864011.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    106. Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015 May; 13(5):515-24. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, National comprehensive cancer network. PMID: 25964637.
      View in: PubMed   Mentions: 190     Fields:    Translation:Humans
    107. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014 Dec; 12(12):1738-61. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. PMID: 25505215.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    108. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer. 2014 Dec 09; 111(12):2268-74. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. PMID: 25349975; PMCID: PMC4264453.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    109. Future of ALK inhibition in non-small-cell lung cancer. Lancet Oncol. 2014 Sep; 15(10):1047-9. Reckamp KL. PMID: 25153539.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    110. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Target Oncol. 2015 Mar; 10(1):65-76. Tabernero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS, Lockhart AC, Hsu CP, Baker NF, Galimi F, Beltran P, Baselga J. PMID: 24816908; PMCID: PMC4317391.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCTClinical Trials
    111. The FEN1 E359K germline mutation disrupts the FEN1-WRN interaction and FEN1 GEN activity, causing aneuploidy-associated cancers. Oncogene. 2015 Feb 12; 34(7):902-11. Chung L, Onyango D, Guo Z, Jia P, Dai H, Liu S, Zhou M, Lin W, Pang I, Li H, Yuan YC, Huang Q, Zheng L, Lopes J, Nicolas A, Chai W, Raz D, Reckamp KL, Shen B. PMID: 24608430; PMCID: PMC4160428.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    112. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 2014 Apr 15; 120(8):1145-54. Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri FR, Engelman JA, Koczywas M, Rajan A, Campbell AK, Gernhardt D, Ruiz-Garcia A, Letrent S, Liang J, Taylor I, O'Connell JP, Jänne PA. PMID: 24501009; PMCID: PMC4164026.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    113. PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res. 2014 May; 12(5):765-74. Krysan K, Kusko R, Grogan T, O'Hearn J, Reckamp KL, Walser TC, Garon EB, Lenburg ME, Sharma S, Spira AE, Elashoff D, Dubinett SM. PMID: 24469837; PMCID: PMC4020971.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    114. EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung. J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1040-4. Scher KS, Saldivar JS, Fishbein M, Marchevsky A, Reckamp KL. PMID: 24029120.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    115. Sexuality, lung cancer, and the older adult: an unlikely trio? J Adv Pract Oncol. 2013 Sep; 4(5):331-40. Williams AC, Reckamp K, Freeman B, Sidhu R, Grant M. PMID: 25032012; PMCID: PMC4093438.
      View in: PubMed   Mentions: 2  
    116. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am J Transl Res. 2013; 5(5):481-96. Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, Walser TC, Rodriguez NL, Pagano PC, Garon EB, Brothers JF, Elashoff D, Lee JM, Spira AE, Sharma S, Fishbein MC, Dubinett SM. PMID: 23977408; PMCID: PMC3745436.
      View in: PubMed   Mentions: 13  
    117. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):645-53; quiz 653. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National comprehensive cancer network. PMID: 23744864.
      View in: PubMed   Mentions: 221     Fields:    Translation:Humans
    118. Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer. PLoS One. 2013; 8(5):e65121. Zhang W, Pal SK, Liu X, Yang C, Allahabadi S, Bhanji S, Figlin RA, Yu H, Reckamp KL. PMID: 23717691; PMCID: PMC3663795.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    119. Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 01; 11(5):562-76. Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National Comprehensive Cancer Network. PMID: 23667206.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    120. Intraventricular chemotherapy for leptomeningeal carcinomatosis from lung cancer: a feasible and beneficial treatment option? J Thorac Oncol. 2013 May; 8(5):523-4. Christoph DC, Reckamp KL. PMID: 23584292.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    121. A 75-year-old man with progressive bronchioalveolar carcinoma. Semin Oncol. 2013 Feb; 40(1):e1-8. Baikadi M, Lovly C, Horn L, Reckamp KL, Noonan K, Laskin J, Morris GJ. PMID: 23391120; PMCID: PMC6607023.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    122. CCL21 Chemokine Therapy for Lung Cancer. Int Trends Immun. 2013 Jan; 1(1):10-15. Sharma S, Zhu L, Srivastava MK, Harris-White M, Huang M, Lee JM, Rosen F, Lee G, Wang G, Kickhoefer V, Rome LH, Baratelli F, St John M, Reckamp K, Chul-Yang S, Hillinger S, Strieter R, Dubinett S. PMID: 25264541; PMCID: PMC4175527.
      View in: PubMed   Mentions: 9  
    123. Phosphatidylinositol-3-kinase pathway. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S383-4. Reckamp KL. PMID: 23160326.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    124. Longitudinal changes in function, symptom burden, and quality of life in patients with early-stage lung cancer. Ann Surg Oncol. 2013 Jun; 20(6):1788-97. Koczywas M, Williams AC, Cristea M, Reckamp K, Grannis FW, Tiep BL, Uman G, Ferrell B. PMID: 23143593; PMCID: PMC3657328.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    125. Non-small cell lung cancer. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1236-71. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM, NCCN (National Comprehensive Cancer Network). PMID: 23054877.
      View in: PubMed   Mentions: 178     Fields:    Translation:Humans
    126. Is benefit of maintenance therapy for NSCLC best defined by progression-free survival? Lancet Oncol. 2012 May; 13(5):435-6. Reckamp KL. PMID: 22512846.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    127. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer. Cancer Lett. 2012 Aug 28; 321(2):101-9. Reckamp KL. PMID: 22306704.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    128. Malignant pleural mesothelioma. J Natl Compr Canc Netw. 2012 Jan; 10(1):26-41. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network. PMID: 22223867.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    129. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011 Nov; 52(11):1684-1689. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. PMID: 22045706; PMCID: PMC5021512.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    130. Novel mechanisms and targets: miscellaneous agents. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1812-4. Reckamp KL. PMID: 22005541.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    131. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. PMID: 21716143; PMCID: PMC3220078.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    132. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 2011 Nov 01; 71(21):6601-10. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W, Scuto A, Weng S, Morosini D, Cao ZA, Zinda M, Figlin R, Huszar D, Jove R, Yu H. PMID: 21920898; PMCID: PMC3206173.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCells
    133. A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Feb; 69(2):505-14. Portnow J, Frankel P, Koehler S, Twardowski P, Shibata S, Martel C, Morgan R, Cristea M, Chow W, Lim D, Chung V, Reckamp K, Leong L, Synold TW. PMID: 21850464; PMCID: PMC3506384.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    134. Combination chemotherapy for older adults with advanced non-small-cell lung cancer. Lancet. 2011 Sep 17; 378(9796):1055-7. Reckamp KL. PMID: 21831419.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    135. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011 Sep; 22(9):2057-2067. Blumenschein GR, Kabbinavar F, Menon H, Mok TSK, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L, Motesanib NSCLC Phase II Study Investigators. PMID: 21321086.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    136. Management of non-small-cell lung cancer in the older adult. Maturitas. 2011 Apr; 68(4):311-21. VanderWalde A, Pal SK, Reckamp KL. PMID: 21295421.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    137. City of Hope Cancer Center hematology-oncology fellowship and hematopoietic stem cell transplantation fellowship. Am J Hematol. 2011 Feb; 86(2):197-8. Krishnan A, Reckamp K, Leong L. PMID: 21264906.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    138. Predictors of finding benefit after lung cancer diagnosis. Psychooncology. 2012 Apr; 21(4):365-73. Thornton AA, Owen JE, Kernstine K, Koczywas M, Grannis F, Cristea M, Reckamp K, Stanton AL. PMID: 21254308.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    139. STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol. 2011; 344:41-59. Lee H, Pal SK, Reckamp K, Figlin RA, Yu H. PMID: 20517723; PMCID: PMC3244828.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    140. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. PMID: 21273177; PMCID: PMC3777729.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    141. Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S487-9. Pal SK, Reckamp KL. PMID: 21102251; PMCID: PMC3192015.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    142. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 2010 Dec 01; 70(23):9599-610. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, Deng J, Forman S, Figlin R, Yu H. PMID: 21118964; PMCID: PMC3017475.
      View in: PubMed   Mentions: 67     Fields:    Translation:AnimalsCells
    143. Thymic malignancies. J Natl Compr Canc Netw. 2010 Nov; 8(11):1302-15. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network. PMID: 21081786.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    144. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer. 2011 Feb 15; 117(4):809-18. Reckamp K, Gitlitz B, Chen LC, Patel R, Milne G, Syto M, Jezior D, Zaknoen S. PMID: 20922800.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    145. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs. 2010 Nov; 19(11):1355-66. Pal SK, Reckamp K, Yu H, Figlin RA. PMID: 20846000; PMCID: PMC3244346.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansAnimals
    146. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 2010 Oct 01; 70(19):7455-64. Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, Wang L, Kowolik C, Deng J, Figlin R, Yu H. PMID: 20841481; PMCID: PMC3058618.
      View in: PubMed   Mentions: 75     Fields:    Translation:AnimalsCells
    147. Consistency of a two clinical site sample collection: a proteomics study. Proteomics Clin Appl. 2010 Sep; 4(8-9):726-38. Wiesner C, Hannum C, Reckamp K, Figlin R, Dubridge R, Roy SM, Lin S, Becker CH, Jones T, Hiller J, Cheville JC, Wilson K. PMID: 21137090.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    148. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010 Jul; 8(7):740-801. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC, NCCN Non-Small Cell Lung Cancer Panel Members. PMID: 20679538.
      View in: PubMed   Mentions: 267     Fields:    Translation:Humans
    149. PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res. 2010 Jun 30; 2(4):356-67. Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, Pak PS, Elashoff D, Reckamp K, Zhang L, Fishbein MC, Sharma S, Dubinett SM. PMID: 20733946; PMCID: PMC2923860.
      View in: PubMed   Mentions: 32  
    150. Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther. 2010 Jul; 9(7):1931-44. Pal SK, Figlin RA, Reckamp K. PMID: 20571071; PMCID: PMC3244351.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    151. Molecular origins of lung cancer: prospects for personalized prevention and therapy. J Thorac Oncol. 2010 Jun; 5(6 Suppl 3):S207-13. Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. PMID: 20502275.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    152. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res. 2010 Jan 01; 16(1):279-90. Blumenschein GR, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A. PMID: 20028752.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    153. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics. 2009 Dec; 8(12):2746-58. Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP. PMID: 19776420; PMCID: PMC2816016.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    154. Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. J Thorac Oncol. 2009 Jul; 4(7):930-5. Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, Simon G, Tsao M, West HJ, Herbst R, Johnson D, Bunn P, Govindan R. PMID: 19550249.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    155. CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer. 2009 Jun 29; 9:213. Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, Strieter RM. PMID: 19563666; PMCID: PMC2708193.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    156. Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol. 2008 Dec; 35(6):590-6. Vora N, Reckamp KL. PMID: 19027463; PMCID: PMC2701401.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    157. An interdisciplinary care approach for integration of palliative care in lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):352-60. Borneman T, Koczywas M, Cristea M, Reckamp K, Sun V, Ferrell B. PMID: 19073518.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    158. The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):340-5. Pal SK, Figlin RA, Reckamp KL. PMID: 19073516.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    159. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep; 6 Suppl 5:S1-20; quiz S21-2. Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. PMID: 18926092.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    160. Chemokines as therapeutic targets in renal cell carcinoma. Expert Rev Anticancer Ther. 2008 Jun; 8(6):887-93. Reckamp KL, Strieter RM, Figlin RA. PMID: 18533798; PMCID: PMC2884168.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    161. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res. 2008 Mar 01; 14(5):1355-62. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, Diamandis EP, Goodglick L. PMID: 18316555.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    162. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol. 2008 Feb; 3(2):117-24. Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM. PMID: 18303430.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    163. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol. 2008 Feb; 3(2):107-10. Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett SM. PMID: 18303428.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    164. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther. 2007 Oct; 7(10):1405-21. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM. PMID: 17944566.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimals
    165. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother. 2007 May-Jun; 30(4):417-24. Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM. PMID: 17457216.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    166. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer. 2006 Nov 03; 5:56. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, Belperio JA, Strieter RM. PMID: 17083723; PMCID: PMC1636662.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    167. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3381-8. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA. PMID: 16740761.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    168. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem. 2006 May; 6(3):209-20. Krysan K, Reckamp KL, Sharma S, Dubinett SM. PMID: 16712449.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimals
    169. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2006 Mar 15; 66(6):3205-13. Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM, Sharma S. PMID: 16540672.
      View in: PubMed   Mentions: 39     Fields:    Translation:AnimalsCells
    170. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol. 2005 Oct 15; 175(8):5351-7. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. PMID: 16210641.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCells
    171. Radiofrequency ablation in lung cancer: promising results in safety and efficacy. Oncology (Williston Park). 2005 Oct; 19(11 Suppl 4):12-21. Suh R, Reckamp K, Zeidler M, Cameron R. PMID: 16366374.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    172. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol. 2005 Aug 01; 175(3):1483-90. Baratelli F, Lin Y, Zhu L, Yang SC, Heuzé-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM. PMID: 16034085.
      View in: PubMed   Mentions: 225     Fields:    Translation:HumansCells
    173. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol. 2005 Jul 15; 175(2):813-9. Sharma S, Zhu L, Yang SC, Zhang L, Lin J, Hillinger S, Gardner B, Reckamp K, Strieter RM, Huang M, Batra RK, Dubinett SM. PMID: 16002678.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    174. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 2005 Jul 15; 65(14):6275-81. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, Dubinett SM. PMID: 16024629.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCells
    175. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer. 2005 Jul; 7(1):30-9. Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, Sharma S, Hazra S, Strieter R, Gardner B, Dubinett SM. PMID: 16098242.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    176. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005 Jun 15; 65(12):5211-20. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. PMID: 15958566.
      View in: PubMed   Mentions: 195     Fields:    Translation:AnimalsCells
    177. PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. J Leukoc Biol. 2005 Aug; 78(2):555-64. Baratelli F, Krysan K, Heuzé-Vourc'h N, Zhu L, Escuadro B, Sharma S, Reckamp K, Dohadwala M, Dubinett SM. PMID: 15908458.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Karen's Networks
    Concepts (521)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (62)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California